Skip to Main Navigation Skip to Content
Collaborative global initiatives in science

Main Content

 

XIX International Symposium on Respiratory Viral Infections

June 22-25, 2017 Berlin, Germany

Preliminary Program/ Invited Speakers

As of March 28, 2017

Chairs

Abdullah Brooks

The Bloomberg School for Public Health, Department of International Health, Johns Hopkins University, Baltimore, Maryland, United States

Arnold Monto

Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States

Albert Osterhaus

Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany

 

Scientific Advisory Board:
Menno de Jong Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Daniel Feikin International Health, John Hopkins, Bloomberg School of Public Health Baltimore, MD, United States
Bradford Gessner Scientific Director, Agence de Medecine Preventitive, Paris, France
Kathy Neuzil University of Maryland School of Medicine, Baltimore, Maryland, United States

 

Thursday, June 22, 2017
15:00 – 18:00 Afternoon Registration
Friday, June 23, 2017 – Day One
7:00 Registration Opens
9:00 Welcome and Introduction to Keynote
9:10 – 9:50 Keynote Address: Novel Intervention Strategies for Respiratory Viruses  Adolfo Garcia-Sastre, Director, Global Health and Emerging Pathogens Institute Icahn School of Medicine at Mount Sinai, New York, NY, United States (confirmed)
Session I Intervention Strategies for RSV – Chair: Daniel Feikin, Associated Professor, International Health, John Hopkins, Bloomberg School of Public Health, Baltimore, MD, United States (confirmed)
9:50 – 10:15 Overview of RSV: Intervention, Vaccination and Therapy – Daniel Feikin, Associated Professor, International Health, John Hopkins, Bloomberg School of Public Health, Baltimore, MD, United States (confirmed)
10:15 – 10:40 Role of Antibodies in Prevention and Treatment of RSV – Tonya Villafana, Senior Director, MedImmune, Gaithersburg, MD, United States (confirmed)
10:40 – 11:05 Maternal Vaccination – Janet Englund, University of Washington, Seattle, Washington, United States (confirmed)
11:05 – 11:30 Coffee Break
11:30 – 11:55 Management of RSV of Adults – Ann R. Falsey, M.D., University of Rochester, School of Medicine, NY, United States (confirmed)
11:55 – 12:15 Oral Presentation: Functional Inactivation of Cellular Gatekeeper p53 During the Time Course of Respiratory Syncytial Virus Infection – Daniela Bandeira Machado, Foundation Merieux, Lyon, France
12:15 – 12:35 Oral Presentation: Harmonization of RSV Antibody Assays for Assessment of Vaccine Immunogenicity – Deborah Higgins, PATH Center for Vaccine Innovation and Access, Seattle, Washington, United States
12:35 – 13:55 Oral Presentation: An Observational Study to Assess Respiratory Syncytial Virus (RSV)-associated Illness in Adults with Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF) – Ann R. Falsey, M.D., University of Rochester, School of Medicine, NY, United States (confirmed)
13:55 -14:30 Lunch
Session II Development and Introduction of New Vaccines – Chair: Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States (confirmed)
14:30 – 14:55 The Use of Adjuvanted Vaccines. Pros and Cons. – Giovanni Della Cioppa, Head of Global Research & Development Center, GSK Vaccines, Siena, Italy (TBC)
14:55 – 15:25 Quadrivalent Influenza Vaccines – Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States (confirmed)
15:25 – 15:50 Should Influenza Vaccine Contain Neuraminidase – Manon Cox, President and CEO, Protein Sciences Corporation (confirmed)
15:50 – 16:15 Recent Experience of LAIV in School Children in the UK – Richard Pebody, Department of Respiratory Diseases, Health Protection Agency, London, United Kingdom (Confirmed)
16:15 – 16:40 Coffee Break
16:40 – 17:00 Oral Presentation: A Phase 2b Study of MEDI7510, an Adjuvanted Post-fusion F Vaccine for the Prevention of RSV in Older Adults – Judith Falloon, MedImmune, Gaithersburg, MD, United States
17:00 – 17:20 Oral Presentation (TBD)
18:00 – 19:30 Welcome Reception
Saturday, June 24, 2017 – Day Two
Session III Vaccination Programs for Prevention of Respiratory Infections – Chair: Kathy Neuzil, University of Maryland School of Medicine, Baltimore, Maryland, United States (confirmed)
9:00 – 9:25 Global Disease Burden of Influenza and RSV – Kathy Neuzil, University of Maryland School of Medicine, Baltimore, Maryland, United States (confirmed)
9:25 – 9:50 Challenges in Vaccine Virus Selection and Vaccine Coverage – Daniel Jernigan, Director, Influenza Division in the National Center for Immunization and Respiratory Diseases, U.S. Center for Disease Control, Atlanta, GA, United States (confirmed)
9:50 – 10: 10 Oral Presentation: Vaccinated Individuals Were Infected with Influenza A(H3N2) Virus: Amino Acid Substitution Patterns Mark the Beginning of 2016-2017 Winter Season – Michal Mandelboim, Sheba Medical Center, Ramat Gan, Israel
10:10 – 10:30 Oral Presentation (TBD)
10:30 – 10:50 Oral Presentation (TBD)
10:50 – 11:20 Coffee Break
11:20 – 11:40 Oral Presentations (TBD)
11:40 – 12:00 Oral Presentations (TBD)
12:00 – 14:00 Lunch
Session IV New Approaches to Vaccine Use – Chair: Bradford Gessner, Scientific Director, Agence de Medecine Preventitive, Paris, France (confirmed)
14:00 – 14:25 Direct and Indirect Affects of Vaccination – Bradford Gessner, Scientific Director, Agence de Medecine Preventitive, Paris, France (confirmed)
14:25 – 14:50 (TBD)
14:50 – 15:10 Oral Presentations (TBD)
15:10 – 15:30 Oral Presentations (TBD)
15:30 – 16:00 Coffee Break
16:00 – 16:20 Oral Presentations (TBD)
16:20 – 16:40 Oral Presentations (TBD)
16:45 – 17:45 Poster Session Reception
Sunday, June 25, 2017 – Day Three
Session V Addressing Emerging and Re-Emerging Threats – Chair: Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (confirmed)
9:00 – 9:25 Emerging and Re-Emerging Threats by Respiratory Viruses – Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (confirmed)
9:25 – 9:50 Current Nipah Threat: Where do we stand? – Heinz Feldmann, National Institute of Health, Intramural Research Program, Hamilton, MT, United States (confirmed)
9:50 – 10:10 Current Avian Influenza Outbreaks. – Are they a Risk to Humans? – Martin Beer, Institutleiter, Friedrich Loeffler Institut, Greifswald-Insel Riems, Germany (confirmed)
10:10 – 10:30 Oral Presentation: Burden of Disease: Estimates of Influenza-associated Mortality in Egypt 2000-2013 – Eman Aly, World Health Organization. Cairo, Egypt
10:30 – 11:00 Coffee Break
11:00 – 11:20 Oral Presentation and Young Investigator Award Recipient: Genomic Characterization of a Novel Human Influenza A(H1N2) variant detected in Brazil – Paola Cristina Resende, Oswaldo Cruz Institute, Rio de Janeiro, Brazil
Session VI Antivirals and Other Treatment Options – Chair: Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (confirmed)
11:20 – 11:55 Overview of Flu: Where do we Stand Today? – Melissa Willis, Therapeutic Branch, BARDA, U.S. Department of Health and Human Services, Washington D.C., United States (confirmed)
11:55 – 14:00 Lunch
14:00 – 14:25 Combination Therapy and Other New Developments in Antiviral Treatment: Where are we in phase II and III studies? – Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (confirmed)
14:25 – 14:45 Oral Presentation: EDP-938, a Novel Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities both In Vitro and In Vivo – Kai Lin, Enanta Pharmaceuticals, Watertown, MA, United States
14:45 – 15:05 Oral Presentations (TBD)
15:05 – 15:25 Oral Presentations (TBD)
15:25 – 16:00 Coffee Break
16:00 – 16:20 Oral Presentations (TBD)
16:20 – 17:00 Panel Discussion – Chair: Abdullah Brooks, The Bloomberg School for Public Health, Department of International Health, Johns Hopkins University, Baltimore, Maryland, United States (confirmed) –  Including:
 
  • Daniel Feikin, Associated Professor, International Health, John Hopkins, Bloomberg School of Public Health, Baltimore, MD, United States
  • Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States
  • Kathy Neuzil, University of Maryland School of Medicine, Baltimore, Maryland, United States
  • Bradford Gessner, Scientific Director, Agence de Medecine Preventitive, Paris, France
  • Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany
  • Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
17:00 – 17:15 Closing Remarks


Register Here